ArticleJournal of oral and maxillofacial pathology : JOMFP
Fibulin-4 expression in potentially malignant disorders and squamous cell carcinoma of oral mucosa-An immunohistochemical study.
Article in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral squamous cell carcinoma (OSCC) is a leading cause of cancer-related deaths, with India accounting for approximately one-fourth of global cases. OSCC often develops from oral potentially malignant disorders like leucoplakia, erythroplakia, and oral submucous fibrosis (OSF), each carrying varying risks for malignant transformation. Fibulin-4, a glycoprotein involved in extracellular matrix (ECM) remodelling, has been implicated in several cancers, but its role in oral tumours remains unexplored. Methodology: Paraffin-embedded sections of oral epithelial dysplasia (OED) ( Results: Significant differences in Fibulin-4 expression were noted across groups. OSCC and OED displayed high proportions of strong Fibulin-4 expression (76-100%), while OSF showed distinct staining patterns mainly in the middle and upper tissue layers. Higher grades of staining intensity were observed in leucoplakia (82.6% were grade 2), OSMF (83.3% were grade 2), and OSCC groups (65.2% were grade 2) than the control group (78% were grade 1). The interobserver reliability and interobserver reproducibility of Fibulin-4 expression evaluated by kappa statistic was excellent( kappa ≥ 0.80). Fibulin-4 expression was high in OSCC, OED, OSF compared to normal oral mucosa and was statistically significant ( Conclusion: Fibulin-4 expression varies significantly across normal mucosa, OED, OSF, and OSCC, suggesting its potential role in oral carcinogenesis and ECM dynamics. Elevated Fibulin-4 expression in OSCC and OED highlights its potential as a biomarker for malignant transformation. Further research is needed to clarify its role and explore its potential as a therapeutic target in oral cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.